Showing results (331-340 of 539) with videos related to
Sort By:
Pageof 54
Bioconjugate Chemistry|September 19, 2002
Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigenH Karacay, R M Sharkey, W J McBride, et al.Pediatric Blood & Cancer|November 17, 2021
Psychosocial care providers' perspectives: Barriers to implementing services for siblings of children with cancerPhoebe Brosnan, Kathryn A Davis, Marcella Mazzenga, et al.Brain Research|July 3, 2023
Evaluating the effect of post-traumatic hypoxia on the development of axonal injury following traumatic brain injury in sheepJessica M Sharkey, Ryan D Quarrington, Justin L Krieg, et al.Radiology|January 30, 2008
Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse modelRobert M Sharkey, Habibe Karacay, Shankar Vallabhajosula, et al.Sleep Advances : a Journal of the Sleep Research Society|July 9, 2024
Does sleep link child maltreatment to depressive symptoms among incoming first-year college students?Darlynn M Rojo-Wissar, Stephanie H Parade, David H Barker, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2003
Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patientsJeffry A Siegel, Dion Yeldell, David M Goldenberg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 30, 1999
The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragmentsS O Leung, Z Qu, H J Hansen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 1999
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphomaM E Juweid, E Stadtmauer, G Hajjar, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 19, 2009
Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphomaRobert M Sharkey, Habibe Karacay, Christine R Johnson, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 1997
Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibodyM Juweid, R M Sharkey, A Alavi, et al.Pageof 54